医疗改革问路（下）——中国医改步入铁腕时代

Core Viewpoint - The article draws a parallel between the myth of Sisyphus and the ongoing challenges of medical reform in China, suggesting that while progress is made, the struggle to balance drug pricing and innovation continues indefinitely [1] Group 1: Medical Reform - In 2018, China introduced a centralized procurement system as part of its medical reform efforts, aimed at combating high drug prices [1] - After seven years of implementation, by 2025, the industry is beginning to oppose the "low-price only" approach, advocating for stable profits for companies to ensure innovation [1] - The medical insurance policy must maintain existing achievements while balancing the interests of the market, government, and the public regarding drug pricing [1]